Software Pioneer Leaves $10 Million to Five Non-Profits in Health and Drug Policy Reform

Half of the total bequest — approximately $5 million — will benefit the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research and educational organization working with the FDA and international regulatory agencies to develop psychedelics and marijuana into prescription treatments for patients with unmet medical needs. The gift will be the largest that MAPS has ever received and will support research into MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). This treatment is currently in Phase 2 pilot studies and is showing very promising results.